OverviewChartNewsTraderScreen

BVT Call 230 IDP 17.01.2025/  DE000VM9QF93  /

Frankfurt Zert./VONT
12/16/2024  10:12:31 AM Chg.-0.001 Bid10:12:31 AM Ask12:20:07 PM Underlying Strike price Expiration date Option type
0.001EUR -50.00% -
Bid Size: -		 -
Ask Size: -		 BIOGEN INC. DL -,000... 230.00 - 1/17/2025 Call
TeleTrader 10/30/2024 Biogen's Q3 revenue down 3% to $2.5 billion
TeleTrader 8/1/2024 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 7/30/2024 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 7/30/2024 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 7/26/2024 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 7/2/2024 Biogen Completes Acquisition of Human Immunology Biosciences
GlobeNewswire 6/28/2024 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire 6/24/2024 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire 6/10/2024 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire 6/3/2024 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire 5/30/2024 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 5/22/2024 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 5/21/2024 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 5/16/2024 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 5/15/2024 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 5/2/2024 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 4/25/2024 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 4/24/2024 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 4/23/2024 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 4/2/2024 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 3/6/2024 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 3/4/2024 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 2/23/2024 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 2/13/2024 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 2/12/2024 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...